Elicio Therapeutics announces completion of Phase 2 AMPLIFY-7P study enrollment

Elicio Therapeutics (ELTX) announced the completion of enrollment in the Phase 2 AMPLIFY-7P study. The randomized Phase 2 study is evaluating a 7-peptide formulation of ELI-002 in patients with mutant KRAS-driven pancreatic ductal adenocarcinoma, PDAC, who are at high risk of relapse following surgery. Elicio previously reported AMPLIFY-7P Phase 1a study results demonstrating a favorable safety profile, robust T-cell responses, antigen spreading and encouraging preliminary DFS data in PDAC patients.